ZyVersa Therapeutics (ZVSA) Competitors $0.65 -0.08 (-10.47%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$0.67 +0.02 (+2.73%) As of 06/13/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ZVSA vs. INAB, CLRB, UBX, CSCI, TRIB, RLYB, BCDA, BGXX, CLDI, and ATHAShould you be buying ZyVersa Therapeutics stock or one of its competitors? The main competitors of ZyVersa Therapeutics include IN8bio (INAB), Cellectar Biosciences (CLRB), Unity Biotechnology (UBX), COSCIENS Biopharma (CSCI), Trinity Biotech (TRIB), Rallybio (RLYB), BioCardia (BCDA), Bright Green (BGXX), Calidi Biotherapeutics (CLDI), and Athira Pharma (ATHA). These companies are all part of the "pharmaceutical products" industry. ZyVersa Therapeutics vs. Its Competitors IN8bio Cellectar Biosciences Unity Biotechnology COSCIENS Biopharma Trinity Biotech Rallybio BioCardia Bright Green Calidi Biotherapeutics Athira Pharma IN8bio (NASDAQ:INAB) and ZyVersa Therapeutics (NASDAQ:ZVSA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, risk, profitability, analyst recommendations, community ranking, earnings and institutional ownership. Do institutionals & insiders have more ownership in INAB or ZVSA? 92.1% of IN8bio shares are owned by institutional investors. Comparatively, 3.9% of ZyVersa Therapeutics shares are owned by institutional investors. 15.5% of IN8bio shares are owned by insiders. Comparatively, 0.2% of ZyVersa Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media favor INAB or ZVSA? In the previous week, IN8bio had 2 more articles in the media than ZyVersa Therapeutics. MarketBeat recorded 5 mentions for IN8bio and 3 mentions for ZyVersa Therapeutics. IN8bio's average media sentiment score of 0.59 beat ZyVersa Therapeutics' score of 0.29 indicating that IN8bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IN8bio 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ZyVersa Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has stronger valuation & earnings, INAB or ZVSA? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIN8bioN/AN/A-$30.01M-$13.57-0.17ZyVersa TherapeuticsN/AN/A-$98.30MN/AN/A Do analysts rate INAB or ZVSA? IN8bio currently has a consensus price target of $180.00, suggesting a potential upside of 7,864.60%. Given IN8bio's stronger consensus rating and higher probable upside, equities analysts plainly believe IN8bio is more favorable than ZyVersa Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IN8bio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00ZyVersa Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk & volatility, INAB or ZVSA? IN8bio has a beta of 0.18, indicating that its share price is 82% less volatile than the S&P 500. Comparatively, ZyVersa Therapeutics has a beta of 0.74, indicating that its share price is 26% less volatile than the S&P 500. Does the MarketBeat Community favor INAB or ZVSA? IN8bio received 23 more outperform votes than ZyVersa Therapeutics when rated by MarketBeat users. However, 75.00% of users gave ZyVersa Therapeutics an outperform vote while only 72.22% of users gave IN8bio an outperform vote. CompanyUnderperformOutperformIN8bioOutperform Votes2672.22% Underperform Votes1027.78% ZyVersa TherapeuticsOutperform Votes375.00% Underperform Votes125.00% Is INAB or ZVSA more profitable? IN8bio's return on equity of -197.15% beat ZyVersa Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets IN8bioN/A -197.15% -130.48% ZyVersa Therapeutics N/A -224.85%-103.22% SummaryIN8bio beats ZyVersa Therapeutics on 10 of the 13 factors compared between the two stocks. Get ZyVersa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ZVSA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZVSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZVSA vs. The Competition Export to ExcelMetricZyVersa TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.11M$6.87B$5.57B$8.50BDividend YieldN/A2.52%5.28%4.16%P/E RatioN/A8.4326.6319.64Price / SalesN/A262.52407.99152.17Price / CashN/A65.8538.2534.64Price / Book0.016.536.964.60Net Income-$98.30M$143.25M$3.23B$248.06M7 Day Performance-0.41%-0.06%-1.13%-0.94%1 Month Performance29.46%11.77%8.59%3.52%1 Year Performance-87.58%3.66%33.63%14.02% ZyVersa Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZVSAZyVersa Therapeutics0.2314 of 5 stars$0.65-10.5%N/A-86.5%$3.11MN/A0.002News CoverageAnalyst UpgradeShort Interest ↑Gap DownINABIN8bio3.561 of 5 stars$0.13-9.8%$6.00+4,387.7%-95.5%$12.14MN/A-0.1820Stock SplitShort Interest ↓High Trading VolumeCLRBCellectar Biosciences2.6731 of 5 stars$0.26+2.8%$12.50+4,669.2%-87.7%$12.08MN/A-0.1510Short Interest ↓Gap DownUBXUnity Biotechnology4.1575 of 5 stars$0.72+2.4%$3.75+423.5%-47.2%$12.04M$240K-0.5560Positive NewsGap DownCSCICOSCIENS BiopharmaN/A$3.81+13.2%N/AN/A$12.00M$9.03M-0.3220TRIBTrinity Biotech1.7985 of 5 stars$0.66+2.7%N/A-81.5%$11.92M$61.56M-0.29480Positive NewsAnalyst RevisionRLYBRallybio3.3355 of 5 stars$0.29-7.4%$10.00+3,394.1%-80.5%$11.91M$848K-0.1840News CoverageHigh Trading VolumeBCDABioCardia3.6978 of 5 stars$2.26+4.6%$25.00+1,006.2%-40.3%$11.70M$3K-0.5440Positive NewsShort Interest ↓BGXXBright GreenN/AN/AN/AN/A$11.47MN/A-1.002Gap DownCLDICalidi Biotherapeutics1.5053 of 5 stars$0.35-1.2%$10.00+2,790.2%N/A$11.14M$50K0.0038High Trading VolumeATHAAthira Pharma2.8745 of 5 stars$0.29-8.8%$13.83+4,752.1%-88.1%$11.13MN/A-0.1040Gap Down Related Companies and Tools Related Companies INAB Alternatives CLRB Alternatives UBX Alternatives CSCI Alternatives TRIB Alternatives RLYB Alternatives BCDA Alternatives BGXX Alternatives CLDI Alternatives ATHA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZVSA) was last updated on 6/14/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGet in stocks now - and get out on this dateGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | Sponsored[First Look] Get in before potential 10X AI announcementsGo for 10X gains from the next big AI announcement — starting as soon as 7 days from now Former floor trade...Masters in Trading | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ZyVersa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ZyVersa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ZVSA Stock Free ZVSA Stock Alerts